ARTICLE

The effects of firocoxib (Previcox™) in geriatric dogs over a period of 90 days

K E Joubert

PO Box 1898, Lonehill, 2062 South Africa. E-mail: hypnyx@wbs.co.za

ABSTRACT

The long-term use of non-steroidal anti-inflammatory agents in geriatric dogs with osteoarthritis has not been well studied in veterinary medicine. This study evaluated the effects of firocoxib administered to dogs over 7 years of age for 90 days. Pain and lameness scores were evaluated by the owner weekly for the 1st month and then biweekly through to the end of the study, the veterinarian evaluated the dogs monthly. Serum chemistry, including urea, creatinine, alanine transferase, aspartate transaminase, bile acids and bilirubin, urine specific gravity and a urine dipstick, were performed at monthly intervals. Forty-five dogs were enrolled into the treatment group and 9 into the control group. A total of 33 dogs completed the trial in the treatment group and 8 in the control group. Lameness and pain scores were found to be significantly lower in the treated group from day 30 for most parameters evaluated. Bile acids (although not comparable to controls, with higher mean value and a high standard deviation in the control group; in addition the control group had increased bile acids at day 0) and urea (within normal reference range provided (WNL)) were significantly different in the treatment group between days 0 and 90. Urea (WNL) on days 30 and 90 and creatinine (WNL) on day 90 were significantly different between the control group and the treatment group. The most common adverse events reported were diarrhoea, vomition, dark faeces and anorexia. This study showed that firocoxib was effective in managing pain associated with osteoarthritis for 90 days. Despite the geriatric high-risk population used for this study, minimal biochemical changes were seen and adverse drug events seen were in agreement with those previously reported.

Keywords: adverse events, canine, lameness, firocoxib, geriatric, long term, non-steroidal anti-inflammatory drugs, pain control

“Full text available only in PDF format”

REFERENCES

1. Aithal G P, Day C P 2007 Nonsteroidal antiinflammatory drug-induced hepatotoxicity. Clinics in Liver Disease 11: 563-575        [ Links ]

2. Armstrong S, Lees P 1999 Effects of R and S enantiomers and a racemic mixture of carprofen on the production and release of proteoglycan and prostaglandin E₂ from equine chondrocytes and cartilage explants. American Journal of Veterinary Research 60: 98-104        [ Links ]

3. Blot L, Marcelis A, Devogelaer J-P, Manicourt D-H 2000 Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. British Journal of Pharmacology 131: 1413-1421        [ Links ]

4. Charrette B, Dupuis J, Moreau M, Daminet S, Hebert P, Grisneaux E 2003 Assessing the efficacy of long-term administration of tolfenamic acid in dogs undergoing femoral head and neck excision. Veterinary Comparative Orthopaedics and Traumatology 16: 232-237        [ Links ]

5. EMEA Scientific Discussion Document, Merial South Africa, Midrand        [ Links ]

6. Doig P A 1999 The long-term tolerance and efficacy of meloxicam in the treatment of chronic osteoarthritis in dogs. In Bennett, D (ed.) Recent advances in non-steroidal anti-inflammatory therapy in small animals. Boehringer-Ingelheim, Paris: 61        [ Links ]

7. Frean S P, Abraham L A, Lees P 1999 In vitro stimulation of equine cartilage proteoglycan synthesis by hyaluronan and carprofen. Research in Veterinary Science 67: 183-190        [ Links ]

8. Hanson P D, Brooks K C, Case J, Conzemius M, Gordon W, Schuessler J, Shelley B, Sifferman R, Drag M, Alva R, Bell L, Romano D, Fleishman C 2006 Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions. Veterinary Therapeutics 7: 127-140        [ Links ]

9. Hazewinkel H A W, vand en Brom W E, Theyse L F H, Pollmeier M, Hanson P D 2008 Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs. Research in Veterinary Science 84: 74-79        [ Links ]

10. Huneault L, Moreau M, Troncy E 2007 A pilot study of long-term, lower dose meloxicam therapy in osteoarthritic dogs. Proceedings of the 32nd Annual World Small Animal Veterinary Congress 2007, Sydney, 19-23 August 2007: 1-2        [ Links ]

11. John A D, Sieber F E 2004 Age associated issues: geriatrics. Anesthesiology Clinics of North America 22: 45-58        [ Links ]

12. Joubert K E 2007 Pre-anaesthetic screening of geriatric dogs. Journal of the South African Veterinary Association 78: 31-35        [ Links ]

13. Lees P 2003 Pharmacology of drugs used to treat osteoarthritis in veterinary practice. Inflammopharmacology 11: 385-399        [ Links ]

14. Lees P, Landoni M F, Giraudel J, Toutain P L 2004 Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest. Journal of Veterinary Pharmacology and Therapeutics 27: 479-490        [ Links ]

15. Lobetti R G, Joubert K E 2000 Effects of administration of nonsteroidal anti-inflammatory drugs before surgery on renal function in clinically normal dogs. American Journal of Veterinary Research 61: 1501-1506        [ Links ]

16. Luna S P L, Basílio A C, Steagall P V M, Machado L P Moutinho F Q, Takahira R K, Brandão C V S 2007 Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. American Journal of Veterinary Research 68: 258-264        [ Links ]

17. MacPhail C M, Lappin M R, Meyer D J, Smith S G, Webster C R L, Armstrong P J 1998 Hepatocellular toxicosis associated with administration of carprofen in 21 dogs. Journal of the American Veterinary Medical Association 212: 1895-1901        [ Links ]

18. McCann M E, Andersen D R, Zhang D, Brideau C, Black W C, Hanson P D, Hickey G J 2004 In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. American Journal of Veterinary Research 65: 503-512        [ Links ]

19. Pelletier J-P, Lajeunesse D, Jovanovic D V, Lascau-Coman V, Jolicoeur F-C, Hilal G, Fernandes J C, Martel-Pelletier J 2000 Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis. Journal of Rheumatology 27:2893-2902        [ Links ]

20. Petruzzelli M, Vacca M, Moschetta A, Cinzia Sasso R C, Palasciano G, van Erpecum K J, Portincasa P 2007 Intestinal mucosal damage caused by non-steroidal anti-inflammatory drugs: role of bile salts. Clinical Biochemistry 40: 503-510        [ Links ]

21. Polzin D J, Osborne C A, Ross S 2005 Chronic kidney disease. In Ettinger S J, Feldman E C (eds) Textbook of veterinary internal medicine (6th edn). Elsevier Saunders, St Louis, Missouri: 1756-1785        [ Links ]

22. Raekallio M R, Hielm-Björkman A K, Kejonen J, Salonen H M, Sankari S M 2006 Evaluation of adverse effects of long-term orally administered carprofen in dogs. Journal of the American Veterinary Medical Association 228: 876-880        [ Links ]

23. Rainsford K D, Skerry T M, Chindemi P, Delaney K 1999 Effects of the NSAIDs meloxicam and indomethacin on cartilage proteoglycan synthesis and joint responses to calcium pyrophosphate crystals in dogs. Veterinary Research Communications 23:101-113        [ Links ]

24. Ryan W G, Moldave K, Carithers D 2006 Clinical effectiveness and safety of a new NSAID, firocoxib: a 1000 dog study. Veterinary Therapeutics 7: 119-126        [ Links ]

25. Steagall P V M, Mantovani F B, Ferreira T H, Salcedo E S, Moutinho F Q, Luna S P L 2007 Evaluation of the adverse effects of oral firocoxib in healthy dogs. Journal of Veterinary Pharmacology and Therapeutics 30: 218-223        [ Links ]

Received: September 2008
Accepted: August 2009